RxDoctor Payments Data

Javier Jurado, MD

Cardiovascular Disease · Evansville, INNPI 1104099142

Payments from drug & device makers

$25,666in general payments, 2019–2025

Across 54 payments — averaging $475.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$15K
  • Boehringer Ingelheim$8K
  • Lilly USA, LLC$990
  • Abbott$459
  • Edwards Lifesciences$174
  • Pfizer$155
  • plus $330 from 9 others

What the payments were for

  • Speaking & faculty fees$23,29091%
  • Travel & lodging$7833%
  • Food & beverage$1,5936%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,666 in reported general payments places this provider in the 80th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$194,841
Medicare patients
1,219
Services billed
2,762

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis85$2,447,753
VyndaqelTafamidis Meglumine18$623,366
FarxigaDapagliflozin Propanediol761$493,893
JardianceEmpagliflozin587$458,542
EntrestoSacubitril/Valsartan379$324,233
EliquisApixaban244$216,888
Repatha SureclickEvolocumab102$85,032
XareltoRivaroxaban82$68,822
VascepaIcosapent Ethyl88$33,648
Praluent PenAlirocumab43$24,093
DapagliflozinDapagliflozin Propanediol36$17,270
CorlanorIvabradine Hcl17$9,912
Ranolazine ErRanolazine93$8,860
NexletolBempedoic Acid15$5,921
Metoprolol Succinate561$5,170

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Vyndaqel, Eliquis$155$3,288,008347 claims
AstraZenecaFarxiga$15,394$493,893761 claims
Boehringer IngelheimJardiance$8,163$458,542587 claims
NovartisEntresto$32$324,233379 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →